Belvedere Trading’s Immunovant IMVT Stock Holding History

Belvedere Trading’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-20,000	Closed	-$843K	–	804
2023 Q4	$843K	Sell	20,000 -20,900	-51%	-$769K	﹤0.01%	106
2023 Q3	$1.57M	Buy	+40,900	New	+$924K	﹤0.01%	58

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Belvedere Trading's IMVT Position: Q4 2023 in Review

Belvedere Trading sold out of Immunovant (IMVT) in Q4 2023, closing a stake of 10,461 shares — an estimated $385K sold.

Belvedere Trading first reported a position in IMVT in Q3 2021 and held it in 2 quarters. The position peaked at $402K in Q3 2023. 228 funds tracked by Wall St. Rank hold IMVT as of Q4 2023.

Belvedere Trading reported no remaining Immunovant position as of Q4 2023 after selling out during the quarter.
Belvedere Trading sold 10,461 Immunovant shares in Q4 2023, an estimated $385K.
Belvedere Trading first reported a position in Immunovant in Q3 2021 and held it in 2 quarters.
Belvedere Trading's Immunovant position peaked at $402K in Q3 2023.
228 funds tracked by Wall St. Rank held Immunovant as of Q4 2023.

Based on Belvedere Trading's 13F filing for Q4 2023, filed 13 Feb 2024.